Today we announced our first xB3 platform technology licensing agreement with Prothena for an undisclosed neurodegenerative disease target as well as the option for three additional neuroscience targets. Under the terms of the agreement, Bioasis will receive an upfront payment of US$1 million and may receive up to an additional US$33 million in options exercise, regulatory and commercial milestone payments, and additional royalties on net sales from the licensed products. 

To learn more, please visit: https://www.bioasis.us/bioasis-announces-xb3-platform-technology-licensing-agreement-with-prothena/

#xB3 #BBB #bloodbrainbarrier #CNS #neuroscience #biotech #pharma #biopharmaceutical #biotechnology #teambioasis #teamprothena $BTI $BIOAF $PRTA